ScoreWhy is Zhejiang Shapuaisi Pharmaceutical Co. Ltd. ?
1
Poor Management Efficiency with a low ROCE of 1.63%
- The company has been able to generate a Return on Capital Employed (avg) of 1.63% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 4.43% and Operating profit at 10.09% over the last 5 years
3
The company has declared Negative results for the last 6 consecutive quarters
- NET PROFIT(HY) At CNY -69.11 MM has Grown at -85.92%
- OPERATING CASH FLOW(Y) Lowest at CNY 16.61 MM
- NET SALES(Q) At CNY 100.17 MM has Fallen at -16.08%
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 0.98%, its profits have risen by 9.7%
- At the current price, the company has a high dividend yield of 0
5
Underperformed the market in the last 1 year
- The stock has generated a return of 0.98% in the last 1 year, much lower than market (China Shanghai Composite) returns of 14.77%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Zhejiang Shapuaisi Pharmaceutical Co. Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zhejiang Shapuaisi Pharmaceutical Co. Ltd.
2.74%
0.10
35.08%
China Shanghai Composite
15.19%
1.01
14.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.43%
EBIT Growth (5y)
10.09%
EBIT to Interest (avg)
-18.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.29
Tax Ratio
4.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.63%
ROE (avg)
1.42%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.45
EV to EBIT
-59.82
EV to EBITDA
71.62
EV to Capital Employed
1.43
EV to Sales
5.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.38%
ROE (Latest)
-3.38%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -24.65% (YoY
PRE-TAX PROFIT(Q)
Highest at CNY 14.03 MM
NET PROFIT(Q)
Highest at CNY 11.83 MM
EPS(Q)
Highest at CNY 0.02
-30What is not working for the Company
NET PROFIT(HY)
At CNY -69.11 MM has Grown at -85.92%
OPERATING CASH FLOW(Y)
Lowest at CNY 16.61 MM
NET SALES(Q)
At CNY 100.17 MM has Fallen at -16.08%
INTEREST(9M)
At CNY 6.43 MM has Grown at 10.42%
ROCE(HY)
Lowest at -7.15%
DEBT-EQUITY RATIO
(HY)
Highest at 5.14 %
CASH AND EQV(HY)
Lowest at CNY 374.67 MM
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.7%
Here's what is working for Zhejiang Shapuaisi Pharmaceutical Co. Ltd.
Pre-Tax Profit
At CNY 14.03 MM has Grown at 153.92%
over average net sales of the previous four periods of CNY -26.01 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 11.83 MM has Grown at 142.38%
over average net sales of the previous four periods of CNY -27.92 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Pre-Tax Profit
Highest at CNY 14.03 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 11.83 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.02
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -24.65% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Zhejiang Shapuaisi Pharmaceutical Co. Ltd.
Net Sales
At CNY 100.17 MM has Fallen at -16.08%
over average net sales of the previous four periods of CNY 119.37 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (CNY MM)
Operating Cash Flow
Lowest at CNY 16.61 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Debt-Equity Ratio
Highest at 5.14 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Interest
At CNY 6.43 MM has Grown at 10.42%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Cash and Eqv
Lowest at CNY 374.67 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Inventory Turnover Ratio
Lowest at 2.7%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
